Highly-Touted Gastrointestinal Surgeon and Metabolism Researcher Dr. Oliver F. Bathe Named Adviser to M Pharmaceutical, Inc.

VANCOUVER, BRITISH COLUMBIA--(Marketwired - July 17, 2015) - M Pharmaceutical Inc., (CSE:MQ)(OTCQB:MPHMF)(T3F1.F) (the "Company"), a Canadian company committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life for people affected by obesity and diabetes, has named highly-touted University of Calgary gastrointestinal surgeon and diabetes researcher Dr. Oliver Frank Bathe, MD, MSc, FRCS(C), FACS, to its Advisory Board, effective immediately.

Dr. Bathe, a graduate of Simon Fraser University, the University of Calgary and the University of British Columbia who currently serves at the Division of Surgical Oncology at the Tom Baker Cancer Centre and is a member of the Julia McFarlane Diabetes Center at the University of Calgary, brings to M Pharmaceutical, Inc. an impressive background in a number of specializations, including metabolomics, cancer surgery, epidemiology, and critical care.

Named a full Professor in the Departments of Surgery and Oncology at the University of Calgary in April of 2012, Dr. Bathe has served as the provincial leader of the Gastrointestinal Tumour Team at the Tom Baker Centre for the past two years.

"The wealth and scope of knowledge associated with Dr. Bathe, especially in areas of diabetes, gastrointestinal and hepatobiliary surgery, and critical care, will only strengthen our company's capacity in the pursuit of excellence with respect to our innovative biomedical technologies," said Dr. Martin Mintchev, President & Chief Executive Officer of M Pharmaceutical, Inc. "Given his expertise in areas of specialization such as gastrointestinal surgery, and diabetes mellitus, he is a natural fit for our company as we move toward the final development and launch of M Pharmaceutical biomedical technologies such as the e-Mosquito, gastro-intestinal neurostimulators and pseudobezoars."

With residencies and clinical fellowships at institutions as varied as St. Paul's Hospital in Vancouver, the University of Miami's Sylvester Comprehensive Cancer Care Centre and University of British Columbia, Dr. Bathe brings with him an international track record in diabetes research, surgery and oncology.

His career has been built not only on the strength of numerous professional awards and scholarships in his fields of expertise, but also on his reputation for teaching and mentorship. His students have gone on to win more than 30 individual awards and scholarships in Canada and throughout North America. Dr. Bathe is also widely-published in his core fields of diabetes mellitus, surgery and oncology.

"We welcome Dr. Bathe to an M Pharmaceutical, Inc. Advisory Board that also includes research and technology leaders such as Douglas Janzen, Dr. Orly Yadid-Pecht and Dr. Michel Fattouche," added Dr. Mintchev. "Their guidance and leadership will add value to our strategic plan around product development and commitment to providing positive solutions for those living with obesity and diabetes."

About M Pharmaceutical Inc.

M Pharmaceutical Inc. is committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life of people affected by obesity and diabetes. The Company currently has or has agreed to acquire the exclusive rights to a family of biomedical technologies including (i) the eMosquito, for automatic and autonomous monitoring of blood glucose by diabetics; (ii) temporary controllable pseudobezoars, an innovative method for non-invasive dynamic gastric volume reduction for weight loss that has been recently tested in blind, placebo-controlled human studies; and (iii) gastrointestinal neurostimulators, using a laparoscopically-implantable technique for the treatment of obesity without permanent anatomical modification of the stomach. Commercial development of eMosquito, Trimeo and Trimtec biomedical technologies will require successful coordination and execution of a wide variety of technology disciplines.

Forward-Looking Statements:

This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the commercialization of the rights to the eMosquito, Trimeo and Trimtec biomedical technologies. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and such factors as the Company failing to complete the commercialization of the eMosquito, Trimeo and Trimtec biomedical technologies.